2025年,港股IPO活动呈现井喷式增长。据统计,有117家公司以发行新股的方式在港交所上市,较2024年大幅增加。其中,生物医药板块异常活跃,映恩生物、恒瑞医药、派格生物等20家生物医药公司集中上市。这些公司中既有成立超过二十年的行业老兵,也不乏技术新秀,技术路线涵盖抗体偶联药物(ADC)、AI制药、双特异性抗体、多肽、小分子等几乎所有前沿领域。表1 2025年港股生物医药板块上市公司资料来源:...
Source Link2025年,港股IPO活动呈现井喷式增长。据统计,有117家公司以发行新股的方式在港交所上市,较2024年大幅增加。其中,生物医药板块异常活跃,映恩生物、恒瑞医药、派格生物等20家生物医药公司集中上市。这些公司中既有成立超过二十年的行业老兵,也不乏技术新秀,技术路线涵盖抗体偶联药物(ADC)、AI制药、双特异性抗体、多肽、小分子等几乎所有前沿领域。表1 2025年港股生物医药板块上市公司资料来源:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.